Psychedelic Alpha report
A lawsuit filed by attorneys on behalf of psychedelic drug developer Reunion Neuroscience alleges that Mindset Pharma “knowingly copied” Reunion’s RE104 (FKA FT-104, when Reunion was part of Field Trip), “and presented that exact composition to the [U.S. Patent and Trademark Office] as its invention.”
The dispute, filed on March 13th in the U.S. District Court for the District of New Jersey, revolves around Reunion’s lead candidate isoprocin glutarate, a hemiglutarate prodrug of 4-HO-DiPT—one of Sasha Shulgin’s TiHKAL compounds. Shulgin described the drug as such: “I truly doubt that there is another psychedelic drug, anywhere, that can match this one for speed, for intensity, for brevity, and sensitive to dose, at least one that is active orally”. At 2-3 hours, the drug has a much shorter trip than that of psilocybin, for example, which might make it a more scalable product. Reunion’s initial indication for the candidate is postpartum depression. (We covered the compound back in a December 2021 Bulletin.)
Read the full story at
Sean Hocking
Source link
